A Phase 1 Study of the Next-Generation ALK/Ros1/TRK Inhibitor Ropotrectinib (TPX-0005) in Patients with Advanced ALK+/ROS1+/TRK+ Cancers (TRIDENT-1)

Alexander Drilon,1 Sai-Hong Ignatius Ou,2 Byoung Chul Cho,3 Dong-Wan Kim,4 Jeeyun Lee,4 Jessica J. Lin,5,6 Wuita Z. Hui,3 Hyo Ryan Kim,3 Tae Min Kim,3 Myung-Jo Ahn,7,8 Ross Camidge,9 John K. Lim,4 Shanna Sotochkinska,4

1Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA; 2Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA, USA; 3Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; 4Seoul National University Hospital, Seoul, Republic of Korea; 5Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; 6Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; 7University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA; 8TTP Therapeutics Inc, San Diego, CA, USA; 9TP Therapeutics Inc, San Diego, CA, USA

INTRODUCTION

Ropotrectinib is a multi-targeted ALK-Ros1-TRK inhibitor with meaningful antitumor activity against both wild-type (WT) and a variety of mutations (including solvent front mutations) of ALK, Ros1, and TRK.

METHOD

Phases 1a and 1b were conducted in patients with advanced ALK+ and/or ROS1+ cancers. A phase 1b expansion and phase 2 study are ongoing.

RESULTS


